Clinical trials: COVID-19 Drug Treatment
- Condition COVID-19 Drug Treatment
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
COVID, Drug Effect
Assessment of Mortality Rates in COVID-19 Infected Populations Treated With Repurposed Medications
This retrospective cohort study will include eligible patients that received a positive COVID-19 test and filled a new prescription for one of the repurposed medications (including hydroxychloroquine, chloroquine, with or without…
- Conditions
- COVID, Drug Effect, Drug Interaction, Risk Reduction
- Trial name
- NCT04432350
- Where
- United States
- Sponsor
- Tabula Rasa HealthCare
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19)
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People With Weakened Immune Systems or at Increased Risk for Poor Outcomes Who Are Hospitalized Due to Severe COVID-19
A Study to Learn About the Medicine Called Nirmatrelvir Used in Combination With Ritonavir in People with Weakened Immune Systems or at Increased Risk for Poor Outcomes who are Hospitalized Due to Severe COVID-19
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Coronavirus Disease 2019 (COVID-19), Immunocompromised, Hospitalization
- Trial name
- EPIC-HOS (NCT05545319)
- Testing
- Nirmatrelvir, Ritonavir
- Where
- 11 sites in United States, Bulgaria
- Sponsor
- Pfizer
SARS-CoV-2, COVID-19
Use and Effectiveness of COVID-19 Vaccines Using State Vaccine Registries and Insurance Claims Data
This study aims to use vaccination information from state vaccine registries linked with HealthVerity insurance claims for the following: to measure how effective the Pfizer-BioNTech vaccine is at preventing post-COVID…
- Conditions
- SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
- Trial name
- NCT05876377
- Testing
- Pfizer-BioNTech COVID-19 mRNA vaccine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Pfizer
COVID-19
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir) in People 12 Years Old or Older With Return of COVID-19 Symptoms and SARS-CoV-2 Positivity After Finishing Treatment With Nirmatrelvir/Ritonavir
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound.
- Trial name
- NCT05567952
- Testing
- nirmatrelvir, ritonavir
- Where
- 84 sites in United States, Canada and 3 more
- Volunteers
- 436 people
- Sponsor
- Pfizer
COVID-19
Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19
The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.
- Trial name
- NCT04603651
- Testing
- Bamlanivimab
- Sponsor
- Eli Lilly and Company
SARS-CoV-2 Infection
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.
- Trial name
- NCT05687877
- Where
- 18 sites in Japan
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
COVID-19
A Study to Learn About Effects of Living With COVID-19 and the Use of the Medicines Nirmatrelvir-Ritonavir in Treating COVID-19.
The purpose of this study is to learn about: effects of living with COVID-19 and how effective is nirmatrelvir-ritonavir in treating COVID-19. This is a study of two groups of COVID-19 patients in Taiwan.
- Trial name
- NCT06085924
- Testing
- SoC, Disease description
- Where
- Taiwan
- Volunteers
- 2,315,187 people
- Sponsor
- Pfizer